SUNNYVALE, Calif., June 15,
2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) announced today that Franco N.
Palomba has joined the company as vice president, chief
accounting officer & controller. Mr. Palomba will be
responsible for the controllership function, including the global
accounting organization and associated budgetary and administrative
operations, as well as financial and regulatory compliance. He will
report to Accuray senior vice president & chief financial
officer Ali Pervaiz.
Mr. Palomba is a skilled executive with more than 30 years of
accounting and finance expertise, primarily in the radiation
therapy industry at Varian Medical Systems, now a part of Siemens
Healthineers. Most recently, he served as vice president of finance
and controller at Ashvattha Therapeutics where he was
responsible for all internal and external resources supporting the
successful completion of the company's first multiyear audit,
establishment of an internal finance team and closing of a major
company funding initiative. Prior to Ashvattha Therapeutics, Mr.
Palomba held various leadership positions at Genomic Health, Inc.,
acquired by Exact Sciences, Varian, and PricewaterhouseCoopers.
"Franco is a well-rounded executive with the deep strategic and
tactical expertise necessary to help advance our global finance
organization and drive the growth of our business. Under his
guidance his teams have delivered significant value including
streamlining processes, reducing debt and increasing income. We
look forward to his leadership at this important time in our
organization's evolution," said Ali
Pervaiz, senior vice president & chief financial officer
at Accuray.
"The opportunity with Accuray will enable me to re-engage in the
radiation therapy industry, an area of particular interest and
importance to me. I've always been impressed by the innovation
behind the organization's technology and the team's dedication to
improving the lives of patients who would benefit from radiation
treatments," said Franco Palomba,
vice president, chief accounting officer & controller at
Accuray. "I'm looking forward to partnering with the global team to
help accelerate the company's growth and build shareholder
value."
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter,
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, expectations related to the
company's growth and building shareholder value. If any of these
risks or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the effect of the COVID-19 pandemic on the operations
of the company and those of its customers and suppliers;
disruptions to our supply chain, including increased logistics
costs; the company's ability to achieve widespread market
acceptance of its products, including new product and software
offerings; the company's ability to develop new products or enhance
existing products to meet customers' needs and compete favorably in
the market, the company's ability to realize the expected benefits
of the China joint venture and
other partnerships; risks inherent in international operations; the
company's ability to effectively manage its growth; the company's
ability to maintain or increase its gross margins on product sales
and services; delays in regulatory approvals or the development or
release of new offerings; the company's ability to meet the
covenants under its credit facilities; the company's ability to
convert backlog to revenue; and such other risks identified under
the heading "Risk Factors" in the company's Quarterly Report on
Form 10-Q, filed with the Securities and Exchange Commission (the
"SEC") on April 29, 2022 and as
updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
+1 (443) 450-4191
aman.patel@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-appoints-franco-n-palomba-as-vp-chief-accounting-officer--controller-301568471.html
SOURCE Accuray Incorporated